The first phase of Liuyang Biomedical Park (National Liuyang Economic and Technological Development Zone) has a planned area of ??13.4 square kilometers, and the current built area is 8 square kilometers; the first phase of the Information Technology Park is 5 square kilometers, and the current built area is 2 square kilometers. kilometers; the food science and technology park has been built with 1 square kilometers. The total investment in industrial enterprises is 7 billion yuan, and the investment in infrastructure is 2.2 billion yuan. Among the industrial enterprises, 70 are pharmaceutical and related enterprises, and the rest are bio-environmental protection, bio-energy and information technology enterprises.
In terms of infrastructure, water plants, sewage plants, central heating, steam supply, substations, broadband networks, etc. have been built. Most of the investment has been solved by self-raised funds by the management committee. Now the park has accumulated tax revenue 2.15 billion yuan and construction loans of 1.1 billion yuan. So far, biomedicine accounts for 65% of the park's total. The leading companies are Wellman Pharmaceuticals, Jiuzhitang Siqi Pharmaceuticals, Laimeikangyuan Pharmaceuticals, Laobaibian Anbang Pharmaceuticals, Jintai Pharmaceuticals, Taier Pharmaceuticals, Erkan Pharmaceuticals and other 43 GMP companies. factory.
Information technology includes Lens Technology, the company with the largest investment in the park, and Interface Optoelectronics, a Taiwan-funded enterprise. They are committed to creating high-end accessories and complete machines such as mobile phone touch screens. They have now become the main suppliers of world-renowned brands in this field. base.
The park has 18 Class I new drugs under research, 294 patents (trademarks), including 56 invention patents, and 14 recognized provincial famous trademarks; it has an engineering (technology) center 23, including 11 at the central and provincial level. After years of development, three distinctive industry clusters have been formed: medicine, information, and food, involving the fields of environmental protection, new materials, and new energy.
In medicine:
(1) Modern Chinese medicine innovation and characteristic Chinese medicine industry cluster. First, the ultra-micro Chinese medicine pieces produced by Chunguang Jiuhui Modern Chinese Medicine Company in the park won the second prize of the National Science and Technology Progress Award in 2009, which was the first in the field of Chinese medicine since the founding of Hunan Province. Second, the chemical structure modification technology of small molecule active ingredients of traditional Chinese medicine developed by Leishuo Chemical and the technology of separation, extraction and purification of monomer compounds of natural products have become industrialized. Third, Zeng Jianguo, a member of the Peasants and Workers Democratic Party who first proposed that standardized extraction of traditional Chinese medicine is a key link in the modernization of traditional Chinese medicine, established a new Meike Bioresources Co., Ltd. in the park. The key technology for the extraction of fresh traditional Chinese medicine developed by him has been widely used in the application of traditional Chinese medicine extracts to human health and animals. Health medicine is actively expanding. Fourth, characteristic traditional Chinese medicine has formed advantages. Jimeng Pharmaceutical's hepatitis C treatment drug Songzhi Pill, Taier Pharmaceutical's poison "Anjunning", and Xuanxia Pharmaceutical's anti-addiction capsules are all national "9th Five-Year Plan" 863 research projects and have been put on the market. In addition, there are The development of traditional Chinese medicine based on the abundant resources of Ginkgo biloba and its series of products, Pueraria lobata and its series of products accounts for more than 30% of the country's output value.
(2) High-end API and preparation industry cluster. With Jiudian, Warnerda, Dino, Wellman, Nonferrous Kaibo, Kangyuan, Dongfeng and other companies as the core, we focus on peramivir, pazufloxacin mesylate, colloidal bismuth pectin, and pantoprazole. Sodium, prulifloxacin, levopropiperazine, levoornidazole, telmisartan and other high-end APIs and corresponding preparations, bio-immobilized invertase technology for large-scale production of 7-ACA, etc., cephalosporin APIs and preparations It is becoming a major product group in the park, with an annual output value of 4 billion yuan, and this industry is expected to reach 10 billion yuan in the next three years.
(3) Anti-tumor drug industry group. First, the national protected traditional Chinese medicine variety Huazheng Huisheng Oral Liquid developed by Harbin Pharmaceutical Cihang Medical Research Institute has received funding from the U.S. government; second, Professor Liu Jun of Hopkinson University and Professor Shen Ben of the University of Wisconsin have won the National Youth Life Award. Changsha Tianci Biomedical Technology Co., Ltd., composed of scholars who won the Science Searle Award, is the first engineering research center in the field of domestic combined biotechnology that closely integrates industry, academia and research. It has developed a new anti-tumor and anti-cancer drug "rapamycin". "Currently, mass production has been achieved, and the price of this raw material in the international market has reached US$100,000 per kilogram. Third, the new anti-cancer drug "Norfosin" developed by Dino Pharmaceutical Co., Ltd. in cooperation with the Academy of Military Sciences with an investment of 280 million yuan, is about to enter clinical practice, and the design and construction of the production workshop has been started.
(4) Pharmaceutical excipients industry.
Hunan Erkang Pharmaceutical Co., Ltd. is a professional pharmaceutical excipient manufacturer with the most complete varieties, largest scale and most complete supporting facilities in China. The company now has 35 domestic exclusive varieties such as silver nitrate, anhydrous sodium carbonate, and weak protein silver. In the 2010 edition of the Pharmacopoeia, there are more than 30 pharmaceutical excipient quality standards that were revised and formulated by the company with the assistance of several provincial drug inspection institutes and the National Pharmacopoeia Committee. We plan to strengthen assistance in management and technological progress to increase the annual output value to more than 3 billion yuan, making our park the main procurement and production center for pharmaceutical excipients in the country.
(5) Biological diagnostic reagent industry group. The individualized drug diagnostic gene chip of Honghao Biology Company, led by Academician Zhou Honghao, the in vitro diagnostic reagents for syphilis and AIDS of Hexinkang Company, and the "Colloidal Gold Immunochromatography Full Quantitative Analyzer" of Botong Biology Company are developing rapidly in the park. Among them, the mature personalized drug treatment gene detection chip kit for hypertension developed by a team led by Academician Zhou Honghao is the first in the world, and its technical level is in an internationally leading position. In the next five years, we hope that this industry and its supporting health service industry will form an industrial scale of 500 to 1 billion yuan.
(6) Vaccine industry. The Bacillus Calmette-Guérin polysaccharide nucleic acid developed by Xiangya Medical College of Central South University was built in our park for production in December 1999. It was acquired by the listed company Jiuzhitang in 2003. It has generated a total tax revenue of more than 300 million yuan in the park. At the same time, the park management committee has cooperated with Canadian listed company Microbix to develop an influenza vaccine project with an annual output of 100 million doses. Once completed, it will be the third largest vaccine base in the world. In addition, the park has signed a strategic cooperation agreement with Peking University Weiming Group, and Beijing Sinovac Biological Products Co., Ltd. is also actively considering building a base in our park.
(7) Functional health care and food industry cluster. It now has 6 functional health care industry groups with health products as the leading industry, including Taier Pharmaceutical, Green Rhyme Biotechnology, and Yikang Biotechnology, with an annual output value of more than 1 billion yuan. In addition, in recent years, Wenzhou and Taiwan food companies have also begun to enter the park. Master Kong, Yanjin Shop, etc. have already settled in the park, adding new vitality to the park.
(8) Animal health pharmaceutical industry cluster. Mainly companies such as Agricultural University Animal Health, Shibilong, Guang'an, and Taifeng, with new veterinary drugs such as Compound Alpinx Injection and polypeptide antibiotics as the main products, this product group strives to account for 30% of the national market share within three years. It has become an important industrial cluster in the base's biological agriculture field.